174 related articles for article (PubMed ID: 34788983)
21. Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.
Salhotra A; Shan Y; Tsai NC; Sanchez JF; Aldoss I; Ali H; Paris T; Spielberger R; Cao TM; Nademanee A; Forman SJ; Chen R
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1264-1268. PubMed ID: 28434928
[TBL] [Abstract][Full Text] [Related]
22. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Chen RW; Li H; Bernstein SH; Kahwash S; Rimsza LM; Forman SJ; Constine L; Shea TC; Cashen AF; Blum KA; Fenske TS; Barr PM; Phillips T; Leblanc M; Fisher RI; Cheson BD; Smith SM; Faham M; Wilkins J; Leonard JP; Kahl BS; Friedberg JW
Br J Haematol; 2017 Mar; 176(5):759-769. PubMed ID: 27992063
[TBL] [Abstract][Full Text] [Related]
23. Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine.
Zimmer P; Mierau A; Bloch W; Strüder HK; Hülsdünker T; Schenk A; Fiebig L; Baumann FT; Hahn M; Reinart N; Hallek M; Elter T
Leuk Lymphoma; 2015 Feb; 56(2):347-52. PubMed ID: 24738942
[TBL] [Abstract][Full Text] [Related]
24. Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
Romaguera JE; Lee HJ; Tarapore R; Prabhu V; Allen J; Schalop L; Zloza A; Ok CY; Sadimin ET; Schenkel J; Badillo M; Wang M
Br J Haematol; 2019 Apr; 185(1):133-136. PubMed ID: 29740811
[No Abstract] [Full Text] [Related]
25. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Geisler CH; Trneny M; Stilgenbauer S; Kaiser F; Doorduijn JK; Salles G; Szymczyk M; Tilly H; Kanz L; Schmidt C; Feugier P; Thieblemont C; Zijlstra JM; Ribrag V; Klapper W; Pott C; Unterhalt M; Dreyling MH
J Clin Oncol; 2020 Jan; 38(3):248-256. PubMed ID: 31804876
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
Edina BC; Rinaldi I
Acta Med Indones; 2022 Apr; 54(2):316-323. PubMed ID: 35818660
[TBL] [Abstract][Full Text] [Related]
27. Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.
Lucijanic M; Jaksic O
Ann Hematol; 2020 Sep; 99(9):2191-2192. PubMed ID: 32556456
[No Abstract] [Full Text] [Related]
28. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
29. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.
Villa D; Sehn LH; Savage KJ; Toze CL; Song K; den Brok WD; Freeman CL; Scott DW; Gerrie AS
Blood Adv; 2020 Aug; 4(15):3486-3494. PubMed ID: 32735654
[TBL] [Abstract][Full Text] [Related]
30. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Rampotas A; Wilson MR; Lomas O; Denny N; Leary H; Ferguson G; McKay P; Ebsworth T; Miller J; Shah N; Martinez-Calle N; Bishton M; Everden A; Tucker D; El-Hassad E; Hennessy B; Doherty D; Prideaux S; Faryal R; Hayat A; Keohane C; Marr H; Gibb A; Pocock R; Lambert J; Lacey R; Elmusharaf N; Clifford R; Eyre TA
Br J Haematol; 2021 Jul; 194(2):365-377. PubMed ID: 33959947
[TBL] [Abstract][Full Text] [Related]
31. Mantle cell lymphoma: a Turkish Multi-Center Study.
Okay M; Meletli O; Kelkitli E; Malkan UY; Turgut M; Buyukasik Y; Tekin F; Demiroglu H; Goker H
J BUON; 2019; 24(5):2084-2089. PubMed ID: 31786879
[TBL] [Abstract][Full Text] [Related]
32. Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.
Shimizu Y; Kaji D; Watanabe O; Yamaguchi K; Kageyama K; Taya Y; Nishida A; Ishiwata K; Takagi S; Yamamoto H; Mori YA; Wake A; Uchida N; Taniguchi S; Yamamoto G
Cancer Med; 2023 Jun; 12(11):12548-12552. PubMed ID: 37199050
[TBL] [Abstract][Full Text] [Related]
33. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Doorduijn JK; Zijlstra JM; Lugtenburg PJ; Kersten MJ; Böhmer LH; Minnema MC; MacKenzie MA; van Marwijk Kooij R; de Jongh E; Snijders TJF; de Weerdt O; van Gelder M; Hoogendoorn M; Leys RBL; Kibbelaar RE; de Jong D; Chitu DA; Van't Veer MB; Kluin-Nelemans HC
Br J Haematol; 2020 Aug; 190(3):385-393. PubMed ID: 32150297
[TBL] [Abstract][Full Text] [Related]
35. Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma.
Fu S; Wang M; Zhao H; Li R; Lairson DR; Giordano SH; Zhao B; Du XL
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e616-e623. PubMed ID: 31563564
[TBL] [Abstract][Full Text] [Related]
36. Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation.
Aurer I
Curr Opin Oncol; 2019 Sep; 31(5):374-379. PubMed ID: 31233483
[TBL] [Abstract][Full Text] [Related]
37. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP
Verhoef G; Robak T; Huang H; Pylypenko H; Siritanaratkul N; Pereira J; Drach J; Mayer J; Okamoto R; Pei L; Rooney B; Cakana A; van de Velde H; Cavalli F
Haematologica; 2017 May; 102(5):895-902. PubMed ID: 28183846
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.
Smith MR; Li H; Gordon L; Gascoyne RD; Paietta E; Forero-Torres A; Kahl BS; Advani R; Hong F; Horning SJ
J Clin Oncol; 2012 Sep; 30(25):3119-26. PubMed ID: 22851557
[TBL] [Abstract][Full Text] [Related]
39. Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.
Bolen CR; Mattiello F; Herold M; Hiddemann W; Huet S; Klapper W; Marcus R; Mir F; Salles G; Weigert O; Nielsen T; Oestergaard MZ; Venstrom JM
Blood; 2021 May; 137(19):2704-2707. PubMed ID: 33512481
[No Abstract] [Full Text] [Related]
40. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
Delarue R; Haioun C; Ribrag V; Brice P; Delmer A; Tilly H; Salles G; Van Hoof A; Casasnovas O; Brousse N; Lefrere F; Hermine O;
Blood; 2013 Jan; 121(1):48-53. PubMed ID: 22718839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]